Mi Jung Lee1, Jung Tak Park2, Tae Ik Chang3, Young Su Joo2,4, Tae-Hyun Yoo2, Sue Kyung Park5, Wookyung Chung6, Yong-Soo Kim7, Soo Wan Kim8, Kook-Hwan Oh9, Shin-Wook Kang2, Kyu Hun Choi2, Curie Ahn9, Seung Hyeok Han10. 1. Department of Internal Medicine, CHA Ilsan Medical Center, CHA University, Goyang-si, Gyeonggi-do, Republic of Korea. 2. Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea. 3. Department of Internal Medicine, NHIS Medical Center, Ilsan Hospital, Goyang-si, Gyeonggi-do, Republic of Korea. 4. Division of Nephrology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea. 5. Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. 6. Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea. 7. Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. 8. Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea. 9. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. 10. Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea hansh@yuhs.ac.
Abstract
BACKGROUND AND OBJECTIVES: Smoking is associated with vascular calcification and a higher risk of cardiovascular disease. In this study, we investigated the association of smoking dose and cessation with coronary artery calcification (CAC) in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From a nationwide, prospective cohort of Korean patients with CKD, 1914 participants were included. Prevalent CAC was defined as an Agatston score >0, using computed tomography. CAC progression was defined as ≥30%/yr increase in Agatston score at the 4-year follow-up examination in patients with baseline CAC. RESULTS: Prevalent CAC was observed in 952 (50%) patients. Compared with never smokers, former smokers had a similar prevalence ratio for CAC, but current smokers had a 1.25-fold higher prevalence ratio (95% confidence interval [95% CI], 1.10 to 1.42). Among former smokers, a lower smoking load of <10 pack-years (prevalence ratio, 0.77; 95% CI, 0.65 to 0.90) and longer duration of smoking cessation (prevalence ratio for 10 to <20 years, 0.85; 95% CI, 0.73 to 0.98: prevalence ratio for ≥20 years, 0.83; 95% CI, 0.73 to 0.96) were associated with lower risk of prevalent CAC compared with current smoking. The prevalence ratios did not differ between never smoking and long-term cessation. However, short-term cessation with heavy smoking load was associated with a higher risk of prevalent CAC (prevalence ratio, 1.21; 95% CI, 1.03 to 1.40) compared with never smoking. CAC progression was observed in 111 (33%) patients with baseline CAC. Compared with never smokers, former smokers showed a similar risk of CAC progression, but current smokers had a higher risk (relative risk, 1.92; 95% CI, 1.30 to 2.86). CONCLUSIONS: In CKD, former smoking with a lower smoking load and long-term cessation were associated with a lower risk of prevalent CAC than current smoking. CAC progression was more pronounced in current smokers.
BACKGROUND AND OBJECTIVES: Smoking is associated with vascular calcification and a higher risk of cardiovascular disease. In this study, we investigated the association of smoking dose and cessation with coronary artery calcification (CAC) in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From a nationwide, prospective cohort of Korean patients with CKD, 1914 participants were included. Prevalent CAC was defined as an Agatston score >0, using computed tomography. CAC progression was defined as ≥30%/yr increase in Agatston score at the 4-year follow-up examination in patients with baseline CAC. RESULTS: Prevalent CAC was observed in 952 (50%) patients. Compared with never smokers, former smokers had a similar prevalence ratio for CAC, but current smokers had a 1.25-fold higher prevalence ratio (95% confidence interval [95% CI], 1.10 to 1.42). Among former smokers, a lower smoking load of <10 pack-years (prevalence ratio, 0.77; 95% CI, 0.65 to 0.90) and longer duration of smoking cessation (prevalence ratio for 10 to <20 years, 0.85; 95% CI, 0.73 to 0.98: prevalence ratio for ≥20 years, 0.83; 95% CI, 0.73 to 0.96) were associated with lower risk of prevalent CAC compared with current smoking. The prevalence ratios did not differ between never smoking and long-term cessation. However, short-term cessation with heavy smoking load was associated with a higher risk of prevalent CAC (prevalence ratio, 1.21; 95% CI, 1.03 to 1.40) compared with never smoking. CAC progression was observed in 111 (33%) patients with baseline CAC. Compared with never smokers, former smokers showed a similar risk of CAC progression, but current smokers had a higher risk (relative risk, 1.92; 95% CI, 1.30 to 2.86). CONCLUSIONS: In CKD, former smoking with a lower smoking load and long-term cessation were associated with a lower risk of prevalent CAC than current smoking. CAC progression was more pronounced in current smokers.
Authors: Joshua D Bundy; Xuan Cai; Julia J Scialla; Mirela A Dobre; Jing Chen; Chi-Yuan Hsu; Mary B Leonard; Alan S Go; Panduranga S Rao; James P Lash; Raymond R Townsend; Harold I Feldman; Ian H de Boer; Geoffrey A Block; Myles Wolf; Edward R Smith; Andreas Pasch; Tamara Isakova Journal: Am J Kidney Dis Date: 2019-03-29 Impact factor: 8.860
Authors: Joshua D Bundy; Jing Chen; Wei Yang; Matthew Budoff; Alan S Go; Juan E Grunwald; Radhakrishna R Kallem; Wendy S Post; Muredach P Reilly; Ana C Ricardo; Sylvia E Rosas; Xiaoming Zhang; Jiang He Journal: Atherosclerosis Date: 2018-02-10 Impact factor: 5.162
Authors: Yiling J Cheng; Timothy S Church; Thomas E Kimball; Milton Z Nichaman; Benjamin D Levine; Darren K McGuire; Steven N Blair Journal: Am J Cardiol Date: 2003-09-01 Impact factor: 2.778
Authors: Wajeh Qunibi; Moustafa Moustafa; Larry R Muenz; David Y He; Paul D Kessler; Jose A Diaz-Buxo; Mathew Budoff Journal: Am J Kidney Dis Date: 2008-04-18 Impact factor: 8.860
Authors: Matthew J Budoff; Rebekah Young; Victor A Lopez; Richard A Kronmal; Khurram Nasir; Roger S Blumenthal; Robert C Detrano; Diane E Bild; Alan D Guerci; Kiang Liu; Steven Shea; Moyses Szklo; Wendy Post; Joao Lima; Alain Bertoni; Nathan D Wong Journal: J Am Coll Cardiol Date: 2013-03-26 Impact factor: 24.094
Authors: Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian Journal: Circulation Date: 2019-03-17 Impact factor: 29.690
Authors: Ute Mons; Aysel Müezzinler; Carolin Gellert; Ben Schöttker; Christian C Abnet; Martin Bobak; Lisette de Groot; Neal D Freedman; Eugène Jansen; Frank Kee; Daan Kromhout; Kari Kuulasmaa; Tiina Laatikainen; Mark G O'Doherty; Bas Bueno-de-Mesquita; Philippos Orfanos; Annette Peters; Yvonne T van der Schouw; Tom Wilsgaard; Alicja Wolk; Antonia Trichopoulou; Paolo Boffetta; Hermann Brenner Journal: BMJ Date: 2015-04-20
Authors: Natalie Staplin; Richard Haynes; William G Herrington; Christina Reith; Alan Cass; Bengt Fellström; Lixin Jiang; Bertram L Kasiske; Vera Krane; Adeera Levin; Robert Walker; Christoph Wanner; David C Wheeler; Martin J Landray; Colin Baigent; Jonathan Emberson Journal: Am J Kidney Dis Date: 2016-04-23 Impact factor: 8.860